LIWANLI Innovation Co., Ltd.

NT$53.90As of Sun 8 Nov 2026, 12:00 UTC
TWSE:3054Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR 8.81%
Div yield 1.48%
ROE 53.52%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) (0.41)
PE TTM 6.062
TSR TTM 122.72%
Mkt cap NT$4.347B
ROIC 17.48%
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$67
24.23%
(34.39%)
Hold 11|3|8|9|1
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.99
1.03
1.05
1.04
11.25%
19.90%
11.25%
2.16%
RevenueNT$M
394.1
405.4
393.9
387.1
3.22%
8.55%
5.32%
1.78%
Peers (US$131.3M)
Cap (US$)
PE
126.8M
19.58x
127.2M
24.59x
Capital
TTM
5Y
10Y
Leveragex
0.690
(0.026)
(0.022)
EBIT/Intx
0.082
0.305
0.213
Own earn%
(14.54)
(4.76)
0.11
Sh yield%
33.73
16.18
16.22
Owners
Insiders/Inst%
12.26
63.05
Short interest%
1.81
SBC / revenue%
1.16
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
9–16
$1 testx
0.0
Incr. ROIC%
34